Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, Is Well-Tolerated and Active in Patients with T-Cell Lymphoma

被引：8
|
作者：
Khodadoust, Michael S.
Feldman, Tatyana A.
Yoon, Dok Hyun
Yannakou, Costas K.
Radeski, Dejan
Kim, Youn H.
Mehta-Shah, Neha
Khot, Amit
Wilcox, Ryan A.
Kim, Won Seog
Horwitz, Steven M.
Buggy, Joseph J.
Hotson, Andrew
Hill, Craig M.
Munneke, Brian
Mahabhashyam, Suresh
Miller, Richard A.
Janc, James W.
Mobasher, Mehrdad
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-137782
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] CPI-818: a selective interleukin-2-inducible T-cell kinase (ITK) inhibitor has clinical activity in dogs with spontaneous T cell lymphoma
    Thamm, D.
    Weishaar, K.
    Das, S.
    Madriaga, A.
    Hill, C.
    Flicker, F.
    Wolfe, B.
    Ng, P.
    Hotson, A.
    Miller, R.
    Buggy, J.
    Janc, J.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E5 - E5
  • [2] A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma
    Mobasher, Mehrdad
    Miller, Richard A.
    Janc, James W.
    Kwei, Long
    Buggy, Joseph J.
    Luciano, Gabriel
    Mohammady, Anahita
    Kim, Won Seog
    Kim, Youn H.
    Khodadoust, Michael S.
    Horwitz, Steven M.
    Radeski, Dejan
    BLOOD, 2019, 134
  • [3] CPI-818: A selective inhibitor of interleukin-2-inducible T-cell kinase (ITK) that inhibits T-cell receptor signaling, promotes Th1 skewing, and achieves objective tumor responses when administered to dogs with T cell lymphomas
    Janc, James W.
    Hill, Craig M.
    Ng, Patrick P.
    Hoston, Andrew N.
    Madriaga, Antonett
    Dao-Pick, Trang P.
    Yeung, Kitman S.
    Hudson, Ryan
    Beausoleil, Anne-Marie
    Bradley, Erin
    Verner, Erik
    Thamm, Douglas H.
    Miller, Richard A.
    Buggy, Joseph J.
    CANCER RESEARCH, 2019, 79 (13)
  • [4] Interleukin-2-Inducible T-Cell Kinase (ITK) Inhibitors for the Treatment of T-Cell Lymphoproliferative Disorders
    Reneau, John C.
    Hwang, Steven R.
    Murga-Zamalloa, Carlos A.
    Buggy, Joseph J.
    Janc, James W.
    Wilcox, Ryan A.
    BLOOD, 2018, 132
  • [5] Interleukin-2-inducible T-cell kinase inhibitors modify functional polarization of human peripheral T-cell lymphoma cells
    Mamand, Sami
    Carr, Matthew
    Allchin, Rebecca L.
    Ahearne, Matthew J.
    Wagner, Simon D.
    BLOOD ADVANCES, 2019, 3 (05) : 705 - 710
  • [6] Comparison of interleukin-2-inducible kinase (ITK) inhibitors and potential for combination therapies for T-cell lymphoma
    Sami Mamand
    Rebecca L. Allchin
    Matthew J. Ahearne
    Simon D. Wagner
    Scientific Reports, 8
  • [7] Comparison of interleukin-2-inducible kinase (ITK) inhibitors and potential for combination therapies for T-cell lymphoma
    Mamand, Sarni
    Allchin, Rebecca L.
    Ahearne, Matthew J.
    Wagner, Simon D.
    SCIENTIFIC REPORTS, 2018, 8
  • [8] Interleukin-2-Inducible T-Cell Kinase Deficiency-New Patients, New Insight?
    Ghosh, Sujal
    Drexler, Ingo
    Bhatia, Sanil
    Gennery, Andrew R.
    Borkhardt, Arndt
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [9] Identification of a New Inhibitor That Stabilizes Interleukin-2-Inducible T-Cell Kinase in Its Inactive Conformation
    Hantani, Rie
    Hanawa, Saya
    Oie, Shohei
    Umetani, Kayo
    Sato, Toshihiro
    Hantani, Yoshiji
    SLAS DISCOVERY, 2019, 24 (08) : 854 - 862
  • [10] Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma
    Horwitz, Steven M.
    Kim, Youn H.
    Foss, Francine
    Zain, Jasmine M.
    Myskowski, Patricia L.
    Lechowicz, Mary Jo
    Fisher, David C.
    Shustov, Andrei R.
    Bartlett, Nancy L.
    Delioukina, Maria L.
    Koutsoukos, Tony
    Saunders, Michael E.
    O'Connor, Owen A.
    Duvic, Madeleine
    BLOOD, 2012, 119 (18) : 4115 - 4122
12345